Podcasts

Discussing Rheumatology: November 2023

Join Professor Iain McInnes in this month's Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the incidence of disease. The first paper, the GBD 2021 Other Musculoskeletal Disorders Collaborators systematically analysed the global burden of musculoskeletal disorders, and used these data to predict prevalence up to 2050 and the second paper, Yvette Meissner and her colleagues used the German RABBIT registry to investigate the relationship between MACE risk and JAK inhibitors, TNF inhibitors, and DMARDs.

Discussing PsA: Bimekizumab in treating bDMARD-naïve PsA & upadacitinib in treating csDMARD and bDMARD IR PsA

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the safety and efficacy of bimekizumab in bDMARD-naïve patients with PsA through 52 weeks and the second is a publication exploring the real-world safety and efficacy of upadacitinib in patients with PsA and an inadequate response to csDMARDs or bDMARDs.

AxSpA Podcast: Safety and Efficacy of Upadacitinib

Professor Hideto Kameda, Professor of Internal Medicine at Toho University in Japan, is joined by Professor Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and a senior consultant and scientific coordinator of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany, Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands as well as, Atul Deodhar Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA, to discuss the safety and efficacy of Upadacitinib.

The first paper evaluated the 52-week safety, tolerability, and efficacy of updacitinib in the SELECT-AXIS 2 study in patients with AS and an inadequate response to bDMARDs and the second paper then goes on to describe, via a narrative review, the safety and efficacy of updacitinib in axSpA

Author Interview: Dr. David Martin, 2023

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr. David Martin, executive medical director at Pfizer in Massachusetts, USA as they discuss his recent paper 'Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors'

Discussing Rheumatology: October 2023

Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology.

In this episode, he discusses two papers that look at the epidemiology of autoimmune diseases. The first paper, the GBD 2021 Rheumatoid Arthritis Collaborators systematically reviewed the global RA burden, and used these data to predict prevalence up to 2050 and the second paper, Nathalie Conrad and her colleagues reported the incidence and prevalence of 19 different autoimmune disorders in the United Kingdom, while also stratifying by age, sex, and socioeconomic status.

To access detailed summary slides for the papers discussed today, visit imidforum.com.

EULAR Recommendations Podcast 2023 with Professor Peter Nash & Dr. Andreas Kerschbaumer

Join Professor Peter Nash from the Griffith University in Brisbane and Dr. Andreas Kerschbaumer of the Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, Austria, as they discuss an important presentation from this year’s EULAR congress. ‘EULAR Recommendations for the Management of Psoriatic Arthritis: 2023 Update’.